
Ocular Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Ocular Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ocular Hypertension - Drugs In Development, 2022, provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape.
Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea and bleeding at the optic nerve head. Treatment includes eye drops to reduce intraocular pressure.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ocular Hypertension - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ocular Hypertension (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 13, 18, 1 and 11 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Ocular Hypertension (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ocular Hypertension - Drugs In Development, 2022, provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape.
Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea and bleeding at the optic nerve head. Treatment includes eye drops to reduce intraocular pressure.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ocular Hypertension - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ocular Hypertension (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 13, 18, 1 and 11 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Ocular Hypertension (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ocular Hypertension (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Ocular Hypertension (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ocular Hypertension (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ocular Hypertension (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ocular Hypertension (Ophthalmology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ocular Hypertension (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ocular Hypertension (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
108 Pages
- Introduction
- Global Markets Direct Report Coverage
- Ocular Hypertension – Overview
- Ocular Hypertension – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Ocular Hypertension – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Ocular Hypertension – Companies Involved in Therapeutics Development
- Aadi Bioscience Inc
- AbbVie Inc
- Aerie Pharmaceuticals Inc
- Angelini Spa
- Betaliq Inc
- Chong Kun Dang Pharmaceutical Corp
- D. Western Therapeutics Institute Inc
- Future Medicine Co Ltd
- Glaukos Corp
- Graybug Vision Inc
- Ikarovec Ltd
- Jenivision Inc
- Kowa Co Ltd
- Laboratoires Thea SA
- Laboratorios Sophia SA de CV
- Lee's Pharmaceutical Holdings Ltd
- MediPrint Ophthalmics Inc
- Neurim Pharmaceuticals Ltd
- NicOx SA
- Noveome Biotherapeutics Inc
- Ocular Therapeutix Inc
- pH Pharma Co Ltd
- Qlaris Bio Inc
- Santen Pharmaceutical Co Ltd
- Senju Pharmaceutical Co Ltd
- Shenzhen Hornetcorn Bio-technology Company Ltd
- Skye Bioscience Inc
- Sun Pharma Advanced Research Company Ltd
- Sun Pharmaceutical Industries Ltd
- Sustained Nano Systems LLC
- Sylentis SAU
- TaeJoon Pharmaceuticals Co Ltd
- ViSci Ltd
- Visus Therapeutics Inc
- Whitecap Biosciences LLC
- Ocular Hypertension – Drug Profiles
- (bimatoprost + timolol) – Drug Profile
- (brimonidine tartrate + ripasudil) – Drug Profile
- (dorzolamide + latanoprost) – Drug Profile
- (latanoprost + netarsudil) – Drug Profile
- (tafluprost + timolol maleate) – Drug Profile
- AGN-193408 SR – Drug Profile
- bamosiran – Drug Profile
- bimatoprost – Drug Profile
- brimonidine tartrate – Drug Profile
- GB-401 SR – Drug Profile
- Gene Therapy for Ocular Hypertension – Drug Profile
- Gene Therapy to Target Matrix Metalloproteinase 1 for Steroid Induced Glaucoma and Ocular Hypertension – Drug Profile
- H-1337 – Drug Profile
- JVGL-1 – Drug Profile
- latanoprost – Drug Profile
- latanoprost SR – Drug Profile
- levobetaxolol hydrochloride – Drug Profile
- LJ-2698 – Drug Profile
- NB-1111 – Drug Profile
- NCX-1660 – Drug Profile
- NCX-1728 – Drug Profile
- NCX-1741 – Drug Profile
- NCX-470 – Drug Profile
- NCX-667 SR – Drug Profile
- nebivolol – Drug Profile
- netarsudil mesylate – Drug Profile
- omidenepag isopropyl – Drug Profile
- piromelatine – Drug Profile
- PRO-122 – Drug Profile
- QLS-101 – Drug Profile
- razuprotafib – Drug Profile
- ripasudil – Drug Profile
- sepetaprost – Drug Profile
- SJP-0130 – Drug Profile
- Small Molecule to Antagonise 5-HT2A and ADRA1 for Ocular Hypertension – Drug Profile
- sovesudil – Drug Profile
- ST-266 – Drug Profile
- Stem Cell Therapy for Articular Cartilage Defect, Cerebral Hemorrhage, Liver Cirrhosis, Pneumoconiosis and Rheumatoid Arthritis – Drug Profile
- timolol – Drug Profile
- timolol maleate – Drug Profile
- timolol maleate CR – Drug Profile
- TJO-002 – Drug Profile
- travoprost – Drug Profile
- travoprost ER – Drug Profile
- travoprost SR – Drug Profile
- VTI-301 SR – Drug Profile
- WB-007 – Drug Profile
- Ocular Hypertension – Dormant Projects
- Ocular Hypertension – Discontinued Products
- Ocular Hypertension – Product Development Milestones
- Featured News & Press Releases
- Apr 11, 2022: Nicox’s NCX 470 Dolomites phase 2 results published in Journal of Glaucoma
- Feb 21, 2022: Nicox granted new patent for NCX 470 in China, extending coverage to 2039
- Feb 11, 2022: Ocular therapeutix announces upcoming presentation of OTX-TIC Phase 1 Clinical Trial at Glaucoma 360
- Dec 16, 2021: Nicox announces first patient in China screened in the ongoing NCX 470 Denali phase 3 trial in glaucoma
- Nov 25, 2021: Notice of application for domestic manufacturing and marketing approval for K-232 treatment for glaucoma and ocular hypertension (ripasudil hydrochloride hydrate and brimonidine tartrate fixed combination eye drop)
- Nov 10, 2021: Nicox’s NCX 470 Dolomites phase 2 results in glaucoma patients to be presented at the AAO 2021 Annual Meeting
- Oct 13, 2021: Aerie reports positive Phase III data for netarsudil ophthalmic solution
- Sep 29, 2021: Nicox’s NCX 470 shows retinal cell protection in a nonclinical model
- Sep 02, 2021: Zhaoke Ophthalmology: Pivotal phase 3 clinical trial of Levobetaxolol hydrochloride eye drops met its primary endpoint
- Jun 23, 2021: Nicox’s NCX 470 dolomites phase 2 results in glaucoma patients to be presented at the World Glaucoma E-Congress 2021
- Jun 21, 2021: Aerie Pharmaceuticals to present update on Rhopressa at the Raymond James Human Health Innovation Conference
- May 14, 2021: SPARC announces positive top-line results from pivotal phase 3 clinical trial of PDP-716 for the treatment of open angle glaucoma or ocular hypertension
- Mar 16, 2021: MediPrint Ophthalmics announces successful completion of its SIGHT-1 phase 2a clinical study
- Jan 20, 2021: Ocular Therapeutix presents interim topline data from the phase 1 clinical trial of OTX-TIC in patients with primary open angle glaucoma or ocular hypertension at the 10th Annual Glaucoma 360 New Horizons Forum
- Dec 11, 2020: Aerpio announces statistically significant topline results from Razuprotafib glaucoma phase 2 trial
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Ocular Hypertension, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Universities/Institutes, 2022
- Table 5: Products under Development by Companies, 2022
- Table 6: Products under Development by Companies, 2022 (Contd..1)
- Table 7: Products under Development by Companies, 2022 (Contd..2)
- Table 8: Products under Development by Universities/Institutes, 2022
- Table 9: Number of Products by Stage and Target, 2022
- Table 10: Number of Products by Stage and Mechanism of Action, 2022
- Table 11: Number of Products by Stage and Route of Administration, 2022
- Table 12: Number of Products by Stage and Molecule Type, 2022
- Table 13: Ocular Hypertension – Pipeline by Aadi Bioscience Inc, 2022
- Table 14: Ocular Hypertension – Pipeline by AbbVie Inc, 2022
- Table 15: Ocular Hypertension – Pipeline by Aerie Pharmaceuticals Inc, 2022
- Table 16: Ocular Hypertension – Pipeline by Angelini Spa, 2022
- Table 17: Ocular Hypertension – Pipeline by Betaliq Inc, 2022
- Table 18: Ocular Hypertension – Pipeline by Chong Kun Dang Pharmaceutical Corp, 2022
- Table 19: Ocular Hypertension – Pipeline by D. Western Therapeutics Institute Inc, 2022
- Table 20: Ocular Hypertension – Pipeline by Future Medicine Co Ltd, 2022
- Table 21: Ocular Hypertension – Pipeline by Glaukos Corp, 2022
- Table 22: Ocular Hypertension – Pipeline by Graybug Vision Inc, 2022
- Table 23: Ocular Hypertension – Pipeline by Ikarovec Ltd, 2022
- Table 24: Ocular Hypertension – Pipeline by Jenivision Inc, 2022
- Table 25: Ocular Hypertension – Pipeline by Kowa Co Ltd, 2022
- Table 26: Ocular Hypertension – Pipeline by Laboratoires Thea SA, 2022
- Table 27: Ocular Hypertension – Pipeline by Laboratorios Sophia SA de CV, 2022
- Table 28: Ocular Hypertension – Pipeline by Lee's Pharmaceutical Holdings Ltd, 2022
- Table 29: Ocular Hypertension – Pipeline by MediPrint Ophthalmics Inc, 2022
- Table 30: Ocular Hypertension – Pipeline by Neurim Pharmaceuticals Ltd, 2022
- Table 31: Ocular Hypertension – Pipeline by NicOx SA, 2022
- Table 32: Ocular Hypertension – Pipeline by Noveome Biotherapeutics Inc, 2022
- Table 33: Ocular Hypertension – Pipeline by Ocular Therapeutix Inc, 2022
- Table 34: Ocular Hypertension – Pipeline by pH Pharma Co Ltd, 2022
- Table 35: Ocular Hypertension – Pipeline by Qlaris Bio Inc, 2022
- Table 36: Ocular Hypertension – Pipeline by Santen Pharmaceutical Co Ltd, 2022
- Table 37: Ocular Hypertension – Pipeline by Senju Pharmaceutical Co Ltd, 2022
- Table 38: Ocular Hypertension – Pipeline by Shenzhen Hornetcorn Bio-technology Company Ltd, 2022
- Table 39: Ocular Hypertension – Pipeline by Skye Bioscience Inc, 2022
- Table 40: Ocular Hypertension – Pipeline by Sun Pharma Advanced Research Company Ltd, 2022
- Table 41: Ocular Hypertension – Pipeline by Sun Pharmaceutical Industries Ltd, 2022
- Table 42: Ocular Hypertension – Pipeline by Sustained Nano Systems LLC, 2022
- Table 43: Ocular Hypertension – Pipeline by Sylentis SAU, 2022
- Table 44: Ocular Hypertension – Pipeline by TaeJoon Pharmaceuticals Co Ltd, 2022
- Table 45: Ocular Hypertension – Pipeline by ViSci Ltd, 2022
- Table 46: Ocular Hypertension – Pipeline by Visus Therapeutics Inc, 2022
- Table 47: Ocular Hypertension – Pipeline by Whitecap Biosciences LLC, 2022
- Table 48: Ocular Hypertension – Dormant Projects, 2022
- Table 49: Ocular Hypertension – Dormant Projects, 2022 (Contd..1)
- Table 50: Ocular Hypertension – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Ocular Hypertension, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products by Top 10 Targets, 2022
- Figure 4: Number of Products by Stage and Top 10 Targets, 2022
- Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Top 10 Routes of Administration, 2022
- Figure 8: Number of Products by Stage and Top 10 Routes of Administration, 2022
- Figure 9: Number of Products by Molecule Types, 2022
- Figure 10: Number of Products by Stage and Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.